No Data
No Data
Plus Therapeutics Delays Quarterly Report Filing
Plus Therapeutics Announces Presentation of New Data on REYOBIQ
Plus Therapeutics: REYOBIQ Shows Clinical Benefit And Safety In ReSPECT-LM Clinical Trial For Patients With Leptomeningeal Metastases
Express News | Plus Therapeutics’ Reyobiq™ Shows Clinical Benefit and Safety in the Respect-Lm Clinical Trial for Patients With Leptomeningeal Metastases (Lm)
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
D. Boral Capital Initiates Plus Therapeutics(PSTV.US) With Hold Rating